RVMD - Revolution Medicines GAAP EPS of $0.99 beats by $2.01 revenue of $0M misses by $0.86M
2023-11-06 16:27:46 ET
- Revolution Medicines press release ( NASDAQ: RVMD ): Q3 GAAP EPS of $0.99 beats by $2.01 .
- Revenue of $0M misses by $0.86M .
- Sees full year 2023 GAAP net loss to be between $385 and $415 million.
- Projects current cash, cash equivalents and investments can fund planned operations into 2025.
For further details see:
Revolution Medicines GAAP EPS of $0.99 beats by $2.01, revenue of $0M misses by $0.86M